Erasca appoints Charles Fuchs as President, R&D; adopts 2026 inducement plan

Erasca, Inc.

Charles S. Fuchs, M.D., M.P.H., appointed President, R&D effective Aug 10, 2026.
Prior roles: CMO at Tubulis (acquired by Gilead), SVP Global Head Oncology at Genentech/Roche, Yale Cancer Center director.
Compensation: $570k base, 45% target bonus, stock options for 1.3M shares vesting over 4 years.
Inducement Plan adopted, reserving 6.2M shares for equity awards without stockholder approval.
Options: 1,278,520 under new Inducement Plan, remainder under 2021 Incentive Plan; exercise price at close on grant date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.